SUMMARY
Mohamad H. Yamani, M.D., is a cardiologist specializing in heart failure and transplant. His translational science research has focused on the role of alpha-3 versus beta-3 integrins, angiotensin receptors, tissue factor, beta-myosin heavy chain, chemokines, chimerism and metalloproteinase induction system in heart transplant patients.
Dr. Yamani's research has culminated in the discovery of a novel protein in heart transplants as evidenced by the National Center for Biotechnology Information search.
Dr. Yamani has served as a member in many professional societies, including the American College of Cardiology, American Heart Association, International Society for Heart & Lung Transplantation, American Transplant Congress, and Heart Failure Society of America. He has spoken on his research findings and clinical experience to national and international scientific gatherings and medical symposia in North America and Europe.
He has also served as principal investigator on several research projects that contributed significantly to patient care, is a reviewer of several major journals and received several major awards related to translational research.
As a translational researcher and clinical investigator, Dr. Yamani has had the honor and privilege to bridge the gap between clinical and basic science.
Focus areas
- Studying genomic variations in heart failure patients to explain why they respond differently to certain therapeutic strategies
- Directing the Heart Failure Clinic at Mayo Clinic in Florida with a goal of providing world-class care to patients
Significance to patient care
The future genome study may help Dr. Yamani and his colleagues choose the ideal therapeutic strategy for their heart failure population, allowing them to avoid unnecessary procedures that may be not only costly but also associated with undesirable outcomes.